Skip to content
DataLookout
Menu

NCT07468656

SCLC Blood Collection Study

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment increased: 25 → 100 participants Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Start date: Oct 2026 to Jan 2027
    • Eligibility criteria expanded, about 34 words
    • Trial arms changed: 0 → 2
    • Study title revised
  2. Notable Start date: Jul 2026 to Oct 2026v3
  3. Notable Start date: May 2026 to Jul 2026v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of blood samples collected
Timeframe: Through study completion, an average of 8 times (Day 1, Day 8, Day 15, Week 6, Week 12, Week 18, Week 24, Week 36)

Arms and interventions

Tarlatamab

Participants receiving tarlatamab as part of their routine cancer care.

Other Systemic Therapies

Participants receiving other systemic therapies as part of their routine cancer care. This category includes, but is not limited to: platinum-etoposide chemotherapy (with or without concurrent radiation), chemoimmunotherapy (e.g., carboplatin/etoposide/atezolizumab, platinum/etoposide/durvalumab), maintenance immunotherapy (e.g., atezolizumab, durvalumab), consolidation immunotherapy (e.g., durvalumab post-chemoradiation for limited stage), lurbinectedin, antibody-drug conjugates (e.g., ifinatamab deruxtecan, sacituzumab govitecan, or other ADCs), topotecan, and any other systemic agents used in the treatment of small cell lung cancer (SCLC).